Light-Activated nails could ease pain from pelvic cancer spread
NCT ID NCT06083896
First seen Jun 25, 2026 · Last updated Aug 13, 2026 · Updated 3 times
Summary
This early-phase trial is testing whether a minimally invasive procedure using special light-activated nails can help stabilize the pelvis in people whose cancer has spread to the bone around the hip socket. Fifty adults with confirmed cancer and visible pelvic metastases will be enrolled. The main goal is to see if they have better function and fewer complications within three months after the procedure.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- photodynamic nails
- What this could lead to
- If it works, this could offer a less invasive way to stabilize pelvic bone tumors, helping patients move better and have less pain.
- What could go wrong
- This is a very early Phase 1 trial with only 50 people, so it may not show clear benefit. There are also risks from the procedure itself, like infection or nail failure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 50 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2023
- Expected to finish
-
Jan 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients must have a histologically confirmed malignancy from prior biopsy of the primary tumor or a metastatic site. Patients with carcinoma, myeloma, and lymphoma may be included in the study. Patients should have metastatic involvement of the periacetabular region that is visible radiographically. Biopsy of acetabular disease is not required for this study. * Age ≥18 years (Illuminoss is approved only for skeletally mature patients) * Suitable candidate for general anesthesia * Ability to understand and the willingness to sign a written informed consent document. * Able and willing to fill out pre-operative and post-operative functional outcome surveys * Absolute neutrophil count ≥ 1,500/mcL * Platelets ≥ 50,000/mcL Exclusion Criteria: * Patients with uncontrolled intercurrent illness (e.g., recent pneumonia or myocardial infarction that would significantly increase risk of general anesthesia) * Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. * Patients with psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study because of the risk of general anesthesia and radiation exposure (fluoroscopy) to the fetus * History of allergic reactions attributed to compounds of similar chemical or biologic composition to dental resins or PET.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Pelvic metastasis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States